At QuidelOrtho, we’re changing lives one test at a time. With precision and passion, we give people the clarity to create better health outcomes. Our focus is providing the intelligence people need in the moments they need them most. To get there, we imagine, invent, push and pursue for more accurate and reliable diagnostics, faster. Since day one, we’ve provided breakthrough solutions to healthcare professionals. Now, we’re creating a clearer picture of health for more people globally. From home to hospital, lab to clinic, we’re helping people everywhere move forward – going the extra mile for everyone we serve. Together, we're advancing diagnostics to power a healthier future.

Resilience (National Resilience, Inc.) is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale.

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the company's partners make progress developing and commercializing their products being developed with ENHANZE®. We are a diverse team, who are committed to bringing therapies and results to patients. It's not enough to be qualified and experienced at what you do, we are looking for people who believe in our mission and match our values. We are building a company where people can pursue their career goals in a supportive and collaborative team environment. Visit www.halozyme.com/careers for more details. We are Halozyme.

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including: Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs. Learn more: www.AjiBio-Pharma.com

Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.

Mapp Biopharmaceutical, Inc. is a biotechnology company located in San Diego, California, United States.

In vitro diagnostic company, specializing in the production of antibodies, controls, blockers including HBR. - Clean Rooms - Filling - Finishing - Packaging - Sub-Assembly - Inventory Space - Kit Manufacturing - Lyophilization - Antibody Production - Medical Device Manufacturing

Nittobo America Inc is an accounting company based out of 25549 Adams Ave, Murrieta, CA, United States.

Neurelis, Inc., is dedicated to innovating life-changing therapeutics that help people with neurological conditions gain greater control over their journeys.

Founded in 1991, BioFilm, Inc, a privately held company, manufactures and distributes high-quality healthcare products that contribute to the well-being of all who use them. Our flagship product, Astroglide Personal Lubricant, is one of the world's top-selling personal lubricants. Our headquarters located in Vista, CA is home to sales, marketing, research & development, quality control, regulatory affairs, customer service, operations, engineering, and distribution.

Rhino Linings Corporation, established in 1988 and headquartered in San Diego, California, is a privately-held corporation and world leader in sprayed and rolled urethane, polyaspartic and epoxy coatings and linings for industrial, municipal and residential applications. In addition to linings and coatings, Rhino Linings elastomeric foams include sealant systems as well as traditional spray foams used in various building/construction, agricultural, petrochemical and custom molding projects. Rhino Linings Corporation has a global retail and industrial applicator network consisting of more than 2000 independently owned businesses in almost 80 countries. For more information about Rhino Linings Corporation, call 877-509-4603 or visit http://www.rhinolinings.com.

At Inhibrx, our mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, we have built a large and diverse pipeline with the potential to impact cancer and orphan diseases through our single domain antibody platform technology. Single domain antibodies (sdAbs) provide a small, simple, modular target binding domain that can be combined in a variety of ways to meet specific needs of unique biological targets. Our sdAb-based therapeutic candidates have been designed to interface with the biology of each target antigen, and can be readily manufactured at high yields with established processes. We have created various multivalent and multispecific therapeutic formats that are each designed to achieve unique functions, including the ability to: - effectively cluster receptors with precisely defined valency; - simultaneously engage multiple antigens or epitopes; - combine synergistic functions in a single molecule; and - restrict therapeutic activity to the tumor microenvironment or other biologically distinct tissue.